This is clearly additional data coming out of the same "Copenhagen" NR Study (PMID 29992272) that earlier reported that 2 x 100o mg/d NR had no effect on "Insulin sensitivity, endogenous glucose production, glucose disposal and oxidation ... resting energy expenditure, lipolysis, oxidation of lipids, or body composition" in obese nondiabetic men, and that certain proponents played up a nonsignificant post hoc suggestion of an effect on liver fat in the subgoup with fatty liver. This new report expands those findings to the other half of the syndrome that is diabetes, finding no effect on beta-function either:
A 12-week randomized, double-blind, placebo-controlled, and parallel-group trial in 40 obese, insulin-resistant males allocated to NR 1,000 mg twice daily (n = 20) or placebo (n = 20).
Methods
2-hour 75 gram oral glucose tolerance tests (OGTT) were performed before and after the intervention ...
Results
NR supplementation during 12 weeks neither affected fasting nor post-glucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. In addition, no changes in circulating adipsin or bile acids were observed following NR supplementation.
Conclusion
The present study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in obese, non-diabetic males. Moreover, bile acid levels in plasma did not change in response to NR supplementation.
PMID 31390002
Edited by Michael, 13 August 2019 - 09:35 PM.